

## Positive Preclinical Results Further Support the PAT-SM6 Multiple Myeloma Programme

- PAT-SM6 shown to work in combination with currently marketed multiple myeloma drugs
- PAT-SM6 demonstrated to be highly effective in a multiple myeloma animal model
- Preclinical data further supports the ongoing development of PAT-SM6 as a novel therapy for multiple myeloma

**Melbourne, Australia; 20 March, 2013:** Patrys Limited (ASX: PAB; “the Company”), a clinical stage biopharmaceutical company, is pleased to report additional preclinical data with its lead anti-cancer product, PAT-SM6. These studies strongly support the ongoing clinical development of PAT-SM6 in the blood cancer, multiple myeloma.

The majority of cancer patients, treated with chemotherapy, usually receive various combinations of different drugs throughout the course of their illness. These drug combinations are designed to include drugs with different mechanisms-of-action (MOA) and, ideally, the drugs work together synergistically to enhance each others anti-tumour effects. Therefore it is important to show that new anti-cancer drugs in development are able to work in synergy with drugs already on the market.

Using a variety of well-established multiple myeloma cell lines, PAT-SM6 was tested either alone (monotherapy) or in double or triple combinations with leading multiple myeloma therapies, Revlimid(Lenalidomide), Velcade(Bortezomib) or Dexamethasone. All of the double combinations tested showed a significant synergistic effect (using the Chou-Talalay method) on the growth of the multiple myeloma cells, as compared to PAT-SM6 alone. The combination of PAT-SM6 plus Revlimid was the most effective. All triple drug combinations tested were *highly* synergistic, with PAT-SM6 plus Revlimid plus Dexamethasone being the most effective at inhibiting the growth of the multiple myeloma cells. This data shows, for the first time, that PAT-SM6 works in combination with already marketed multiple myeloma drugs and that such double or triple combinations work significantly better than when the drugs are used as monotherapies.

When used as a monotherapy, PAT-SM6 was also shown to be highly effective in a mouse model of multiple myeloma. The 5T33 mouse model was chosen as it closely mimics human disease. Both tumour burden in the bone-marrow and serum paraprotein levels (M protein) are able to be measured. In this model, mice with established multiple myeloma were treated with 6-8 doses (range 0.1-30mg/kg) of PAT-SM6 over a 3-4 week period. As compared to the control mice, those treated with >10mg/kg of PAT-SM6 showed a statistically significant reduction in both tumour load (up to 54%) and serum paraprotein levels (up to a 48% reduction). Importantly, there was no toxicity observed in the PAT-SM6 treated mice.

“This exciting preclinical data adds to an already existing database that continues to support our clinical programme with PAT-SM6.” said Patrys' CEO, Dr Marie Roskrow.

“Showing that our antibody works in synergy with marketed multiple myeloma drugs is important and such information will help us in the design of future clinical trials in which PAT-SM6 will be tested with other multiple myeloma drugs. There is no doubt that prospective partners for this programme will be looking for such data. Additionally being able to show that PAT-SM6 works effectively in an animal model with an aggressive type of multiple myeloma is also exciting.”

PAT-SM6 is currently undergoing a Phase I/IIa clinical trial in patients with refractory or relapsed multiple myeloma at the University Hospital of Wurzburg, Germany. The second cohort of patients is currently being recruited into the study.

- Ends -

**For further information, please contact:**

Patrys Limited:

Dr. Marie Roskrow  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

Patrys IR:

Rebecca Wilson  
Buchan Consulting  
P: 0417 382 391  
[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Patrys Media:

Shevaun Cooper  
Buchan Consulting  
P: +61 3 9866 4722  
[scooper@buchanwe.com.au](mailto:scooper@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibody therapies for cancer. More information can be found at [www.patrys.com](http://www.patrys.com).

**About PAT-SM6:**

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to multiple myeloma PAT-SM6 has shown particularly strong promise. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action. Patrys has successfully completed a Phase I clinical trial to evaluate PAT-SM6 as a therapy for melanoma.

**About Multiple Myeloma:**

Multiple myeloma is a type of bone marrow cancer arising from plasma cells, and new therapies are desperately needed to treat patients who become resistant to established chemotherapeutics. There is an estimated 200,000 cases worldwide and the incidence is increasing. The five-year survival of patients is approximately 40% (at 10 years ~20%). Despite new marketed therapies, multiple myeloma remains largely incurable and fatal. The multiple myeloma market is dominated by three major products: Revlimid, Velcade and Thalidomide with combined net sales greater than US\$4.4 Billion in 2011.